Recent news on Piperacillin

Orchid’s turnover rises to Rs 934cr during FY06-07  -  May 4, 2007
Moneycontrol.com,This inspection will help in the subsequent approval and launch of key products, Piperacillin+Tazobactam and other non-antibiotics in the US.

Tazobactam Plus Piperacillin Shows Benefits in Children With Lower ...  -  Apr 9, 2007
DG News...[Presentation title: Comparison of Sulbactam/Ampicillin and Tazobactam/Piperacillin for the Treatment of Lower Respiratory Tract Infection in Paediatric

China Medicine Significantly Broadens Product Portfolio  -  Apr 17, 2007
PR-Inside.com (Pressemitteilung),A number of these products generated significant sales such as Piperacillin Sodium and Sulbactam, Sodium (Antibiotics) and Monosialogangliosides,

Scientific Results Presented at ECCMID Demonstrate Well ...  -  Apr 5, 2007
WebWire (press release),In one study, ceftobiprole showed greater in vitro potency than piperacillin/tazobactam against Pseudomonas aeruginosa (P2026).

Growth zone ahead  -  Feb 11, 2007
Economic Times,The company’s key molecules include Ceftriaxone, Cefprozil and Tazobactum-Piperacillin. Its focus on niche markets has helped it to maintain fairly high

The shares of Orchid Chemicals and Pharmaceuticals are trading ...  -  Jan 31, 2007
Myiris.com,...for these antibiotics is worth USD 700 million or Rs 31.50 billion. Orchid will also launch pencillin-based product, Tazobactum-Piperacillin, in Europe.

Orchid Chemicals to enter European market  -  Jan 30, 2007
Myiris.com,Orchid will also launch pencillin-based product, Tazobactum-Piperacillin, in Europe. This product is likely to go off-patent next month and was to be

Prevnar, Enbrel and Effexor drive Wyeth growth  -  Jan 31, 2007
Pharma Times (subscription),Sales of the gastrointestinal drug Protonix (pantoprazole) were flat at $419.6 million, while Wyeth's Zosyn (piperacillin/tazobactam) antibiotic climbed 21%

Business News  -  Dec 20, 2006
American Digital Networks (press release),...period in 0.5% of patients treated with ertapenem, 0.3% of patients treated with piperacillin/tazobactam and 0% of patients treated with ceftriaxone.

Business News  -  Dec 20, 2006
American Digital Networks (press release),...period in 0.5% of patients treated with ertapenem, 0.3% of patients treated with piperacillin/tazobactam and 0% of patients treated with ceftriaxone.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional